हिंदी में पढ़ें

Glenmark Pharmaceuticals

Glenmark Pharma gets USFDA nod for cholesterol lowering drug

Glenmark Pharma gets USFDA nod for cholesterol lowering drug

Fri, Jun 28, 2019

Glenmark Pharmaceuticals Friday said it has received final approval from the US health regulator for Ezetimibe and Simvastatin tablets, used for treating high levels of cholesterol in the blood.

Top 5 stocks in focus on August 8: Glenmark, Merck to Techno Electric, here are the 5 newsmakers of the day

Top 5 stocks in focus on August 8: Glenmark, Merck to Techno Electric, here are the 5 newsmakers of the day

Wed, Aug 08, 2018

Glenmark Pharmaceuticals has received final approval from the US health regulator, USFDA, for Colesevelam Hydrochloride for oral suspension, used to lower cholesterol levels in the blood. The approved product is a generic version of Daiichi Sankyo Inc’s Welchol.

From HCL Tech, Maruti Suzuki to PVR, here are 5 stock picks for the week

From HCL Tech, Maruti Suzuki to PVR, here are 5 stock picks for the week

Sun, Jun 10, 2018

CPI, WPI and IIP will be presented in upcoming week and domestic indices will move as per the performances of these indicators.

TRENDING NOW

Glenmark share price hits 52-week low, tanks 9% post Q4 FY18 results

Glenmark share price hits 52-week low, tanks 9% post Q4 FY18 results

Wed, May 30, 2018

Glenmark said results are not comparable to the corresponding quarter of the previous year, as the company through its partner Endo had launched Ezetimibe in the US in December 2016 and was entitled to an exclusivity on the product.

How Glenmark Pharma won this Candid Powder battle against lookalike rival

How Glenmark Pharma won this Candid Powder battle against lookalike rival

Thu, May 24, 2018

Pharma company Glenmark Pharmaceuticals, which manufactures and sells Candid Dusting Powder, has recently won a trademark and copyright battle in the Bombay High Court, against a lookalike brand, which sold a dusting powder by the name ‘Candidat’.

Post GST domestic pharma companies to face headwinds in 1HFY18

Post GST domestic pharma companies to face headwinds in 1HFY18

Mon, Jun 05, 2017

It has been a long and dreary quarter for pharmaceutical companies in Q4 wherein most posted a decline in net profit and things are not looking too good for the Indian pharma companies in the first half of FY18 as well.

Glenmark Pharmaceuticals receives ANDA approval for Atomoxetine capsule

Glenmark Pharmaceuticals receives ANDA approval for Atomoxetine capsule

Wed, May 31, 2017

The Glenmark Pharmaceuticals has been granted permission by the United States Food & Drug Administration (U.S. FDA) for Atomoxetine capsules.

Glenmark receives tentative approval Fingolimod Capsules; shares down

Glenmark receives tentative approval Fingolimod Capsules; shares down

Mon, Mar 20, 2017

Glenmark’s current portfolio consists of 112 products authorized for distribution in the US marketplace.

Glenmark Pharma's Q3 net profit rise by 143% to Rs 477 crore

Glenmark Pharma's Q3 net profit rise by 143% to Rs 477 crore

Thu, Feb 02, 2017

The company's total income increased to Rs 2549.5 crore in Q3FY17 as compared to Rs 1780.4 crore in Q3FY16.

India Inc's overseas borrowings down 44% to $1.2 billion in July

India Inc's overseas borrowings down 44% to $1.2 billion in July

Fri, Aug 26, 2016

India Inc's overseas borrowings fell by 44% to $1.2 billion (nearly Rs 7,983.3 crore) in July this year as against $2.14 billion (nearly Rs 14,236.9 crore) in the same period a year ago.

Glenmark Pharma net profit rise 24%; Europe segment major contributor

Glenmark Pharma net profit rise 24%; Europe segment major contributor

Fri, Aug 12, 2016

Glenn Saldanha, Chairman & MD, Glenmark Pharmaceuticals said, “In the first quarter of this financial year, nearly all our businesses have rebounded strongly and we have seen good growth across all operating regions except Latam.

Load More

LIVE TV

By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

x